C81.0A
Nodular lymphocyte predominant Hodgkin lymphoma, in remission
Clinical Classification Guidelines
Medical Intelligence & Overview
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a type of lymphoma, which is a cancer that begins in the lymphatic system. When this condition is diagnosed and treated successfully, and there are no signs of the disease for a period of time, it is said to be in remission. The ICD-10 code C81.0A refers specifically to NLPHL that has entered remission, indicating that treatment has been effective and the cancer is not currently active. Understanding this condition helps patients grasp the significance of remission and the ongoing monitoring required.
Causes & Symptoms
Clinical Causes: Genetic mutations that lead to abnormal lymphocyte growth Possible environmental factors, though specific causes are not fully understood Family history of lymphomas or other blood cancers Previous exposure to certain infections or chemicals, though no direct cause-and-effect has been established
Key Symptoms: Painless swelling of lymph nodes in the neck, armpits, or groin Persistent fatigue or tiredness Unexplained weight loss Night sweats and fever Itching skin or skin rashes Lower abdominal discomfort or swelling in some cases
Diagnostic & Treatment
Diagnosis Path: Diagnosing NLPHL typically involves a combination of medical history review, physical examinations, and tests such as imaging scans (e.g., CT scans or PET scans). A definitive diagnosis often requires a biopsy, where a small sample of lymph node tissue is examined under a microscope to identify cancerous cells. In cases of remission, regular follow-up tests are necessary to monitor for potential recurrence.
Treatment Protocols: Chemotherapy: Using powerful drugs to destroy cancer cells Radiation therapy: Targeted radiation to eliminate remaining cancerous tissue Immunotherapy: Boosting the body’s immune response to fight remaining lymphoma cells Watchful waiting: In some remission cases, careful monitoring without active treatment may be recommended Follow-up care: Regular check-ups, imaging, and blood tests to monitor for signs of recurrence
Clinical Advice & FAQs
Billing Guidance
Is C81.0A a billable ICD-10 code?
Yes, C81.0A is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C81.0A?
Clinical documentation must specify the nature of Nodular lymphocyte predominant Hodgkin lymphoma, in remission and any associated comorbidities for accurate reporting.
Cite this Clinical Reference